 | • レポートコード：GIR-107A13990 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、123ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療機器 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、良性前立腺肥大症治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。良性前立腺肥大症治療の種類別市場規模（医薬品、低侵襲手術、レーザー治療、その他）、用途別市場規模（病院、外来手術センター、専門クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・良性前立腺肥大症治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Abbott、Allergan plc、Astellas Pharma、Asahi Kasei Corporation、Boehringer Ingelheim GmbH、GlaxoSmithKline、Pfizer、Sanofi、Teva Pharmaceutical Industries、Merck、Boston Scientific Corporation、Teleflex Incorporated、Endo International、Urologix、LISA Laser、Olympus ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：医薬品、低侵襲手術、レーザー治療、その他 ・用途別分析2016年-2026年：病院、外来手術センター、専門クリニック、その他 ・良性前立腺肥大症治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・良性前立腺肥大症治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・良性前立腺肥大症治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・良性前立腺肥大症治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・良性前立腺肥大症治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Benign Prostatic Hyperplasia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Benign Prostatic Hyperplasia Treatment size is estimated to be USD 7574.7 million in 2026 from USD 6664.1 million in 2020, with a change XX% between 2020 and 2021. The global Benign Prostatic Hyperplasia Treatment market size is expected to grow at a CAGR of 3.3% for the next five years.
Market segmentation
Benign Prostatic Hyperplasia Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Drug Class
Minimally Invasive Surgeries
Laser Therapy
Others
Market segment by Application, can be divided into
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
Market segment by players, this report covers
Abbott
Allergan plc
Astellas Pharma
Asahi Kasei Corporation
Boehringer Ingelheim GmbH
GlaxoSmithKline
Pfizer
Sanofi
Teva Pharmaceutical Industries
Merck
Boston Scientific Corporation
Teleflex Incorporated
Endo International
Urologix
LISA Laser
Olympus
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Treatment
1.2 Classification of Benign Prostatic Hyperplasia Treatment by Type
1.2.1 Overview: Global Benign Prostatic Hyperplasia Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type in 2020
1.2.3 Drug Class
1.2.4 Minimally Invasive Surgeries
1.2.5 Laser Therapy
1.2.6 Others
1.3 Global Benign Prostatic Hyperplasia Treatment Market by Application
1.3.1 Overview: Global Benign Prostatic Hyperplasia Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Global Benign Prostatic Hyperplasia Treatment Market Size & Forecast
1.5 Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast by Region
1.5.1 Global Benign Prostatic Hyperplasia Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Benign Prostatic Hyperplasia Treatment Market Size by Region, (2016-2021)
1.5.3 North America Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Benign Prostatic Hyperplasia Treatment Market Drivers
1.6.2 Benign Prostatic Hyperplasia Treatment Market Restraints
1.6.3 Benign Prostatic Hyperplasia Treatment Trends Analysis
2 Company Profiles
2.1 Abbott
2.1.1 Abbott Details
2.1.2 Abbott Major Business
2.1.3 Abbott Benign Prostatic Hyperplasia Treatment Product and Solutions
2.1.4 Abbott Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Abbott Recent Developments and Future Plans
2.2 Allergan plc
2.2.1 Allergan plc Details
2.2.2 Allergan plc Major Business
2.2.3 Allergan plc Benign Prostatic Hyperplasia Treatment Product and Solutions
2.2.4 Allergan plc Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Allergan plc Recent Developments and Future Plans
2.3 Astellas Pharma
2.3.1 Astellas Pharma Details
2.3.2 Astellas Pharma Major Business
2.3.3 Astellas Pharma Benign Prostatic Hyperplasia Treatment Product and Solutions
2.3.4 Astellas Pharma Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Astellas Pharma Recent Developments and Future Plans
2.4 Asahi Kasei Corporation
2.4.1 Asahi Kasei Corporation Details
2.4.2 Asahi Kasei Corporation Major Business
2.4.3 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Product and Solutions
2.4.4 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Asahi Kasei Corporation Recent Developments and Future Plans
2.5 Boehringer Ingelheim GmbH
2.5.1 Boehringer Ingelheim GmbH Details
2.5.2 Boehringer Ingelheim GmbH Major Business
2.5.3 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Product and Solutions
2.5.4 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
2.6 GlaxoSmithKline
2.6.1 GlaxoSmithKline Details
2.6.2 GlaxoSmithKline Major Business
2.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Product and Solutions
2.6.4 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 GlaxoSmithKline Recent Developments and Future Plans
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Benign Prostatic Hyperplasia Treatment Product and Solutions
2.7.4 Pfizer Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Pfizer Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Benign Prostatic Hyperplasia Treatment Product and Solutions
2.8.4 Sanofi Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Teva Pharmaceutical Industries
2.9.1 Teva Pharmaceutical Industries Details
2.9.2 Teva Pharmaceutical Industries Major Business
2.9.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Product and Solutions
2.9.4 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.10 Merck
2.10.1 Merck Details
2.10.2 Merck Major Business
2.10.3 Merck Benign Prostatic Hyperplasia Treatment Product and Solutions
2.10.4 Merck Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Merck Recent Developments and Future Plans
2.11 Boston Scientific Corporation
2.11.1 Boston Scientific Corporation Details
2.11.2 Boston Scientific Corporation Major Business
2.11.3 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Product and Solutions
2.11.4 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Boston Scientific Corporation Recent Developments and Future Plans
2.12 Teleflex Incorporated
2.12.1 Teleflex Incorporated Details
2.12.2 Teleflex Incorporated Major Business
2.12.3 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Product and Solutions
2.12.4 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Teleflex Incorporated Recent Developments and Future Plans
2.13 Endo International
2.13.1 Endo International Details
2.13.2 Endo International Major Business
2.13.3 Endo International Benign Prostatic Hyperplasia Treatment Product and Solutions
2.13.4 Endo International Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Endo International Recent Developments and Future Plans
2.14 Urologix
2.14.1 Urologix Details
2.14.2 Urologix Major Business
2.14.3 Urologix Benign Prostatic Hyperplasia Treatment Product and Solutions
2.14.4 Urologix Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Urologix Recent Developments and Future Plans
2.15 LISA Laser
2.15.1 LISA Laser Details
2.15.2 LISA Laser Major Business
2.15.3 LISA Laser Benign Prostatic Hyperplasia Treatment Product and Solutions
2.15.4 LISA Laser Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 LISA Laser Recent Developments and Future Plans
2.16 Olympus
2.16.1 Olympus Details
2.16.2 Olympus Major Business
2.16.3 Olympus Benign Prostatic Hyperplasia Treatment Product and Solutions
2.16.4 Olympus Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Olympus Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Benign Prostatic Hyperplasia Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Benign Prostatic Hyperplasia Treatment Players Market Share
3.2.2 Top 10 Benign Prostatic Hyperplasia Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Benign Prostatic Hyperplasia Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Benign Prostatic Hyperplasia Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Benign Prostatic Hyperplasia Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Application (2016-2021)
5.2 Benign Prostatic Hyperplasia Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
6.2 North America Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
6.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Country
6.3.1 North America Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)
6.3.2 United States Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
7.2 Europe Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
7.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country
7.3.1 Europe Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)
7.3.2 Germany Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7.3.3 France Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region
8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Region (2016-2026)
8.3.2 China Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.5 India Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
9.2 South America Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
9.3 South America Benign Prostatic Hyperplasia Treatment Market Size by Country
9.3.1 South America Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country
10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Benign Prostatic Hyperplasia Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Benign Prostatic Hyperplasia Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Benign Prostatic Hyperplasia Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Benign Prostatic Hyperplasia Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Region (2021-2026)
Table 6. Abbott Corporate Information, Head Office, and Major Competitors
Table 7. Abbott Major Business
Table 8. Abbott Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 9. Abbott Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Allergan plc Corporate Information, Head Office, and Major Competitors
Table 11. Allergan plc Major Business
Table 12. Allergan plc Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 13. Allergan plc Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Astellas Pharma Corporate Information, Head Office, and Major Competitors
Table 15. Astellas Pharma Major Business
Table 16. Astellas Pharma Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 17. Astellas Pharma Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Asahi Kasei Corporation Corporate Information, Head Office, and Major Competitors
Table 19. Asahi Kasei Corporation Major Business
Table 20. Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 21. Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Boehringer Ingelheim GmbH Corporate Information, Head Office, and Major Competitors
Table 23. Boehringer Ingelheim GmbH Major Business
Table 24. Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 25. Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 27. GlaxoSmithKline Major Business
Table 28. GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 29. GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Pfizer Corporate Information, Head Office, and Major Competitors
Table 31. Pfizer Major Business
Table 32. Pfizer Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 33. Pfizer Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Sanofi Corporate Information, Head Office, and Major Competitors
Table 35. Sanofi Major Business
Table 36. Sanofi Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 37. Sanofi Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 39. Teva Pharmaceutical Industries Major Business
Table 40. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 41. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Merck Corporate Information, Head Office, and Major Competitors
Table 43. Merck Major Business
Table 44. Merck Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 45. Merck Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Boston Scientific Corporation Corporate Information, Head Office, and Major Competitors
Table 47. Boston Scientific Corporation Major Business
Table 48. Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 49. Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Teleflex Incorporated Corporate Information, Head Office, and Major Competitors
Table 51. Teleflex Incorporated Major Business
Table 52. Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 53. Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Endo International Corporate Information, Head Office, and Major Competitors
Table 55. Endo International Major Business
Table 56. Endo International Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 57. Endo International Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Urologix Corporate Information, Head Office, and Major Competitors
Table 59. Urologix Major Business
Table 60. Urologix Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 61. Urologix Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. LISA Laser Corporate Information, Head Office, and Major Competitors
Table 63. LISA Laser Major Business
Table 64. LISA Laser Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 65. LISA Laser Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Olympus Corporate Information, Head Office, and Major Competitors
Table 67. Olympus Major Business
Table 68. Olympus Benign Prostatic Hyperplasia Treatment Product and Solutions
Table 69. Olympus Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Global Benign Prostatic Hyperplasia Treatment Revenue (USD Million) by Players (2019-2021)
Table 71. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Players (2019-2021)
Table 72. Breakdown of Benign Prostatic Hyperplasia Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 73. Benign Prostatic Hyperplasia Treatment Players Head Office, Products and Services Provided
Table 74. Benign Prostatic Hyperplasia Treatment Mergers & Acquisitions in the Past Five Years
Table 75. Benign Prostatic Hyperplasia Treatment New Entrants and Expansion Plans
Table 76. Global Benign Prostatic Hyperplasia Treatment Revenue (USD Million) by Type (2016-2021)
Table 77. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Type (2016-2021)
Table 78. Global Benign Prostatic Hyperplasia Treatment Revenue Forecast by Type (2021-2026)
Table 79. Global Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2021)
Table 80. Global Benign Prostatic Hyperplasia Treatment Revenue Forecast by Application (2021-2026)
Table 81. North America Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 82. North America Benign Prostatic Hyperplasia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 83. North America Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 84. North America Benign Prostatic Hyperplasia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 85. North America Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 86. North America Benign Prostatic Hyperplasia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 87. Europe Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 88. Europe Benign Prostatic Hyperplasia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 89. Europe Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 90. Europe Benign Prostatic Hyperplasia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 91. Europe Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 92. Europe Benign Prostatic Hyperplasia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 93. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 94. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 95. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 96. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 97. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Region (2016-2021) & (USD Million)
Table 98. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Region (2021-2026) & (USD Million)
Table 99. South America Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 100. South America Benign Prostatic Hyperplasia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 101. South America Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 102. South America Benign Prostatic Hyperplasia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 103. South America Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 104. South America Benign Prostatic Hyperplasia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 105. Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 106. Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 107. Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 108. Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 109. Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 110. Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Benign Prostatic Hyperplasia Treatment Picture
Figure 2. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type in 2020
Figure 3. Drug Class
Figure 4. Minimally Invasive Surgeries
Figure 5. Laser Therapy
Figure 6. Others
Figure 7. Benign Prostatic Hyperplasia Treatment Revenue Market Share by Application in 2020
Figure 8. Hospitals Picture
Figure 9. Ambulatory Surgical Centers Picture
Figure 10. Specialty Clinics Picture
Figure 11. Others Picture
Figure 12. Global Benign Prostatic Hyperplasia Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Benign Prostatic Hyperplasia Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Region (2016-2026)
Figure 15. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Region in 2020
Figure 16. North America Benign Prostatic Hyperplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Benign Prostatic Hyperplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Benign Prostatic Hyperplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Benign Prostatic Hyperplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Benign Prostatic Hyperplasia Treatment Market Drivers
Figure 22. Benign Prostatic Hyperplasia Treatment Market Restraints
Figure 23. Benign Prostatic Hyperplasia Treatment Market Trends
Figure 24. Abbott Recent Developments and Future Plans
Figure 25. Allergan plc Recent Developments and Future Plans
Figure 26. Astellas Pharma Recent Developments and Future Plans
Figure 27. Asahi Kasei Corporation Recent Developments and Future Plans
Figure 28. Boehringer Ingelheim GmbH Recent Developments and Future Plans
Figure 29. GlaxoSmithKline Recent Developments and Future Plans
Figure 30. Pfizer Recent Developments and Future Plans
Figure 31. Sanofi Recent Developments and Future Plans
Figure 32. Teva Pharmaceutical Industries Recent Developments and Future Plans
Figure 33. Merck Recent Developments and Future Plans
Figure 34. Boston Scientific Corporation Recent Developments and Future Plans
Figure 35. Teleflex Incorporated Recent Developments and Future Plans
Figure 36. Endo International Recent Developments and Future Plans
Figure 37. Urologix Recent Developments and Future Plans
Figure 38. LISA Laser Recent Developments and Future Plans
Figure 39. Olympus Recent Developments and Future Plans
Figure 40. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Players in 2020
Figure 41. Benign Prostatic Hyperplasia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 42. Global Top 3 Players Benign Prostatic Hyperplasia Treatment Revenue Market Share in 2020
Figure 43. Global Top 10 Players Benign Prostatic Hyperplasia Treatment Revenue Market Share in 2020
Figure 44. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 45. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Type in 2020
Figure 46. Global Benign Prostatic Hyperplasia Treatment Market Share Forecast by Type (2021-2026)
Figure 47. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Application in 2020
Figure 48. Global Benign Prostatic Hyperplasia Treatment Market Share Forecast by Application (2021-2026)
Figure 49. North America Benign Prostatic Hyperplasia Treatment Sales Market Share by Type (2016-2026)
Figure 50. North America Benign Prostatic Hyperplasia Treatment Sales Market Share by Application (2016-2026)
Figure 51. North America Benign Prostatic Hyperplasia Treatment Revenue Market Share by Country (2016-2026)
Figure 52. United States Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Canada Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Mexico Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Europe Benign Prostatic Hyperplasia Treatment Sales Market Share by Type (2016-2026)
Figure 56. Europe Benign Prostatic Hyperplasia Treatment Sales Market Share by Application (2016-2026)
Figure 57. Europe Benign Prostatic Hyperplasia Treatment Revenue Market Share by Country (2016-2026)
Figure 58. Germany Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. France Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. United Kingdom Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Russia Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Italy Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Asia-Pacific Benign Prostatic Hyperplasia Treatment Sales Market Share by Type (2016-2026)
Figure 64. Asia-Pacific Benign Prostatic Hyperplasia Treatment Sales Market Share by Application (2016-2026)
Figure 65. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue Market Share by Region (2016-2026)
Figure 66. China Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Japan Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South Korea Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. India Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Southeast Asia Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Australia Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. South America Benign Prostatic Hyperplasia Treatment Sales Market Share by Type (2016-2026)
Figure 73. South America Benign Prostatic Hyperplasia Treatment Sales Market Share by Application (2016-2026)
Figure 74. South America Benign Prostatic Hyperplasia Treatment Revenue Market Share by Country (2016-2026)
Figure 75. Brazil Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Argentina Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Middle East and Africa Benign Prostatic Hyperplasia Treatment Sales Market Share by Type (2016-2026)
Figure 78. Middle East and Africa Benign Prostatic Hyperplasia Treatment Sales Market Share by Application (2016-2026)
Figure 79. Middle East and Africa Benign Prostatic Hyperplasia Treatment Revenue Market Share by Country (2016-2026)
Figure 80. Turkey Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Saudi Arabia Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. UAE Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. Methodology
Figure 84. Research Process and Data Source
世界の良性前立腺過形成（BPH）治療市場予測（～2024年） Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infec…- 世界の良性前立腺肥大症治療薬市場 2021：企業別、地域別、種類・用途別 The Benign Prostate Hyperplasia Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tra…
- 良性前立腺過形成薬の世界市場 2019年版：種類別（アルファブロッカー、5-アルファレダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他）、用途別（病院、クリニック、その他） Description Scope of the Report: The global Benign Prostate Hyperplasia Drugs market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, …
- 世界の前立腺動脈塞栓術（PAE）市場 2021：企業別、地域別、種類・用途別 The Prostatic Arterial Embolization (PAE) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization,…
- 良性再発性肝内胆汁うっ滞（BRIC）画像診断装置の世界市場 2019年版：種類別（X線、MRI、CT、核イメージング）、用途別（病院、イメージングセンター） Scope of the Report: The worldwide market for Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Resea…